Results 281 to 290 of about 48,575 (332)
Some of the next articles are maybe not open access.
American Journal of Psychiatry, 2022
OBJECTIVE Binge-eating disorder, the most prevalent eating disorder, is a serious public health problem associated with obesity, psychiatric and medical comorbidities, and functional impairments.
C. Grilo +5 more
semanticscholar +1 more source
OBJECTIVE Binge-eating disorder, the most prevalent eating disorder, is a serious public health problem associated with obesity, psychiatric and medical comorbidities, and functional impairments.
C. Grilo +5 more
semanticscholar +1 more source
Effect of Extended-Release Naltrexone on Alcohol Consumption: A Systematic Review and Meta-analysis.
Addiction, 2021AIMS 1) Estimate the effect of extended-release naltrexone compared with placebo on alcohol consumption in patients with alcohol use disorder (AUD). 2) Conduct pre-planned subgroup analyses to test whether being abstinent when initiating treatment (lead ...
Charles E. Murphy +4 more
semanticscholar +1 more source
Naltrexone and Conventionality
The American Journal of Drug and Alcohol Abuse, 1978This study examines the effect of conventionality on whether patients who were scheduled for naltrexone took it, and on treatment outcomes for patients who did take it. It is based on admission and case record data for 147 male opiate addicts who enrolled in New York Medical College's Multitrack Abstinence Program. Naltrexone-taking is examined against
Daniel C. Remine +3 more
openaire +3 more sources
CNS Drugs, 2010
Oral morphine/naltrexone extended release capsules comprise the selective mu-opioid receptor agonist morphine in a sustained-release formulation combined with a sequestered core of the mu-opioid receptor antagonist naltrexone for use in the management of moderate to severe pain.
Lesley J. Scott, Sean T. Duggan
openaire +3 more sources
Oral morphine/naltrexone extended release capsules comprise the selective mu-opioid receptor agonist morphine in a sustained-release formulation combined with a sequestered core of the mu-opioid receptor antagonist naltrexone for use in the management of moderate to severe pain.
Lesley J. Scott, Sean T. Duggan
openaire +3 more sources
NALTREXONE IN CHILDREN WITH AUTISM
Journal of the American Academy of Child & Adolescent Psychiatry, 1998Item does not contain ...
Jan K. Buitelaar +2 more
openaire +3 more sources
Journal of Substance Abuse Treatment, 1985
Naltrexone (Trexan R), a long acting, orally affective narcotic antagonist was approved by the Food & Drug Administration in November, 1984 for use as an adjunct in the treatment of Opioid Addiction. This research capsule will explore what is known about naltrexone, and the most appropriate ways of using the drug.
openaire +5 more sources
Naltrexone (Trexan R), a long acting, orally affective narcotic antagonist was approved by the Food & Drug Administration in November, 1984 for use as an adjunct in the treatment of Opioid Addiction. This research capsule will explore what is known about naltrexone, and the most appropriate ways of using the drug.
openaire +5 more sources
Naltrexone implant and blood naltrexone levels over pregnancy
Australian and New Zealand Journal of Obstetrics and Gynaecology, 2003Approximately 80–90% of all women using intravenous heroin are of reproductive age. Although heroin use can cause menstrual irregularities such as amenorrhoea, oligomenorrhea and suppression of ovulation, pregnancy is not uncommon. (1) Maternal heroin use during pregnancy is associated with an increased risk of a number of adverse maternal and ...
Hulse, Gary K +3 more
openaire +4 more sources
Clinical Experience with Naltrexone
The American Journal of Drug and Alcohol Abuse, 1975(1975). Clinical Experience with Naltrexone. The American Journal of Drug and Alcohol Abuse: Vol. 2, No. 3-4, pp. 365-377.
Robert A. Greenstein +3 more
openaire +3 more sources
1981
The clinical efficacy of naltrexone together with psychotherapy was compared to that of naltrexone alone in 22 detoxified heroin addicts. The combination of treatments fostered better retention in treatment and greater likelihood of opiate abstinence than naltrexone alone.
Resnick Rb, Stone-Washton N, Washton Am
openaire +3 more sources
The clinical efficacy of naltrexone together with psychotherapy was compared to that of naltrexone alone in 22 detoxified heroin addicts. The combination of treatments fostered better retention in treatment and greater likelihood of opiate abstinence than naltrexone alone.
Resnick Rb, Stone-Washton N, Washton Am
openaire +3 more sources